--- title: "Immatics (IMTX) news: offering" url: "https://aibio.space/companies/immatics-n-v/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IMTX offering news: Immatics agrees to sell shares and warrants at $8.69 in $150 million offering. Immatics N.V. (NASDAQ: IMTX), Germany." --- IMTX Immatics N.V. NASDAQ · Germany # Immatics (IMTX) news IMTX offering news Financings · 2026-08-26 ## [Immatics agrees to sell shares and warrants at $8.69 in $150 million offering](https://aibio.space/news/immatics-agrees-sell-shares-warrants-8-69-150-million-offering/) Immatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024. ## Latest Immatics news We have not published a story on Immatics yet. When there is news, it will appear here. ## Immatics at a glance - **Ticker**: IMTX - **Listing**: NASDAQ - **Country**: Germany - **Cash, Dec 31, 2025**: €469.3 million ### Related companies - [Dermapharm Holding](https://aibio.space/companies/dermapharm/) XETR: DMP - [Biofrontera](https://aibio.space/companies/biofrontera-b8fk/) XETR: B8FK - [Bayer](https://aibio.space/companies/bayer/) XETR: BAYN - [Merck KGaA](https://aibio.space/companies/merck-mrk-xetr/) XETR: MRK - [Formycon](https://aibio.space/companies/formycon/) XETR: FYB - [Pentixapharm Holding](https://aibio.space/companies/pentixapharm/) XETR: PTP - [Heidelberg Pharma](https://aibio.space/companies/heidelberg-pharma/) XETR: HPHA - [Bio-Gate](https://aibio.space/companies/bio-gate/) XETR: BIG ### Also on NASDAQ - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) AQST - [Aclarion](https://aibio.space/companies/aclarion/) ACON - [HeartBeam](https://aibio.space/companies/heartbeam/) BEATW - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) ACAD - [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NRSN - [Jyong Biotech](https://aibio.space/companies/jyong-biotech/) MENS ## Immatics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [€183.8 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | [€148.1 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | | Net income (loss) | [-€196.4 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | [€15.2 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | | Cash from operations | [-€176.6 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | [-€158.0 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | | Cash and equivalents | [€345.9 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | [€236.7 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | | Short-term investments | [€123.4 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | [€367.7 million](https://www.sec.gov/Archives/edgar/data/1809196/000119312526092529/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €345.9 million, plus short-term investments of €123.4 million, €469.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Immatics Has Immatics raised money recently? Our latest story on this, dated Aug 26, 2026: "Immatics agrees to sell shares and warrants at $8.69 in $150 million offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immatics-agrees-sell-shares-warrants-8-69-150-million-offering/). What is the ticker symbol of Immatics? Immatics N.V. trades under the ticker IMTX on NASDAQ. Where is Immatics listed? Immatics N.V. is listed on NASDAQ. Our directory also records these other listings: DUS:4A3; FWB:4A3; GETTEX:4A3; HAM:4A3; HAN:4A3; LS:A2P72S; LSX:A2P72S; MUN:4A3; SWB:4A3; TRADEGATE:4A3; XETR:4A3. What is the SEC CIK of Immatics? The SEC Central Index Key (CIK) for Immatics N.V. is 1809196. Its filings are on SEC EDGAR. How many shares does Immatics have outstanding? 134,071,432 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05. Which country or territory is Immatics listed under? Our directory records Immatics N.V. under Germany. What does Immatics do? Our directory classifies Immatics N.V. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Immatics? The ISIN recorded for Immatics N.V. is NL0015285941. Does aibio.space cover Immatics? aibio.space lists Immatics N.V. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Immatics incorporated? SEC records list its state or country of incorporation as P7. What is the latest Immatics (IMTX) stock news? Our latest story on Immatics, dated Aug 26, 2026: "Immatics agrees to sell shares and warrants at $8.69 in $150 million offering". Immatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024. [Source](https://aibio.space/news/immatics-agrees-sell-shares-warrants-8-69-150-million-offering/). Is Immatics a smaller reporting company? SEC records list Immatics N.V.'s filer category as: Accelerated filer. Where is Immatics headquartered? SEC records list its business address as PAUL EHRLICH-STRASSE 15, TUBINGEN, Germany, 72076. When does Immatics's fiscal year end? Immatics N.V.'s fiscal year ends on December 31, per SEC records. What did Immatics last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-08-26. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1809196/000119312526368946/d153472d6k.htm). ## Investor discussion: Immatics Members talk about Immatics (IMTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Immatics, newest first. Each line links the filing it comes from. 1. 2026-08-26 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809196/000119312526368946/d153472dex991.htm) 2. 2025-12-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1809196/000119312525308352/d746192d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IMTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-IMTX/). ## SEC filings and registration - **SEC name**: Immatics N.V. - **CIK**: 1809196 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IMTX (Nasdaq) - **State or country of incorporation**: P7 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: PAUL EHRLICH-STRASSE 15, TUBINGEN, Germany, 72076 - **Phone**: 49 7071 5397 700 - **Shares outstanding**: 134,071,432 as of 2025-12-31 (20-F filed 2026-03-05) - **Former names**: Immatics B.V. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000119312526368946/d153472d6k.htm) filed 2026-08-26 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000119312526354715/imtx-20260630.htm) filed 2026-08-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000095010326009230/dp248681_6k.htm) filed 2026-06-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000095010326008259/dp247175_6k.htm) filed 2026-06-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000095010326008113/dp247360_6k.htm) filed 2026-06-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000119312526218152/immatics_n.v._6-k_q126.htm) filed 2026-05-12 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000095010326005970/dp245406_6k.htm) filed 2026-04-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1809196/000095010326005872/dp245235_6k.htm) filed 2026-04-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001809196), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Immatics N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMTX, recorded under Germany. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Immatics N.V. - **Ticker**: IMTX - **Listing**: NASDAQ - **Country or territory**: Germany - **Business scope**: Pharmaceuticals: Major - **ISIN**: NL0015285941 - **Other listed symbols**: DUS:4A3; FWB:4A3; GETTEX:4A3; HAM:4A3; HAN:4A3; LS:A2P72S; LSX:A2P72S; MUN:4A3; SWB:4A3; TRADEGATE:4A3; XETR:4A3 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IMTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/immatics-n-v/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immatics (IMTX) news: offering", 2026-10-31, https://aibio.space/companies/immatics-n-v/